Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes

Molecular and Cellular Biochemistry

Volumn 351, Issue 1-2, 2011, Pages 197-205

  Balasubramanyam, M ^a   Aravind, S ^a   Gokulakrishnan, K ^a   Prabu, P ^a   Sathishkumar, C ^a   Ranjani, H ^a   Mohan, V ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

Asian Indians; Inflammation; Insulin resistance; miR 146a; miRNA; Type 2 diabetes

Indexed keywords

CYTOKINE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 6; MESSENGER RNA; MICRORNA; MICRORNA 146A; ORAL ANTIDIABETIC AGENT; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TARGETING; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; MICRORNAS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953726990     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0727-3     Document Type: Article

References (44)

1. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793-1801 (Pubitemid 44033299)
2. Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, Mohan V (2006) Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance - the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 55:1232-1238 (Pubitemid 44215943)
3. Gokulakrishnan K, Deepa R, Mohan V (2008) Association of high sensitivity C-reactive protein [hsCRP] and tumour necrosis factor-alpha [TNF-alpha] with carotid intimal medial thickness in subjects with different grades of glucose intolerance - the Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem 41:480-485
4. Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, Papasteriades C, Raptis SA (2007) Visfatin, TNFα and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 39:758-763
5. Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M (2009) Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and Type 2 diabetes patients. Mol Cell Biochem 324:173-181
6. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
7. Lynn FC (2009) Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 20:452-459
8. Lindsay MA (2008) microRNAs and the immune response. Trends Immunol 29:343-351
9. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481-12486 (Pubitemid 44267285)
10. Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X (2009) MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183:2150-2158
11. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10:R101
12. Alberti KG, Zimmet PZ (1998) Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO Consultation. Diabet Med 15:539-553
13. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S, Mohan V (2003) The Chennai Urban Rural Epidemiology Study (CURES) - study design and methodology (urban component) (CURES-I). J Assoc Physicians India 51:863-870 (Pubitemid 41279865)
14. Balasubramanyam M, Kimura M, Aviv A, Gardner JP (1993) Kinetics of calcium transport across the lymphocyte plasma membrane. Am J Physiol 265:C321-C327 (Pubitemid 23270299)
15. Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248
16. Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA (2008) Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 31:2338-2343
17. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999-3004 (Pubitemid 38327724)
18. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H (2008) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58:1284-1292 (Pubitemid 351705917)
19. Sonkoly E, Stahle M, Pivarcsi A (2008) MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 33:312-315 (Pubitemid 351550660)
20. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60:1065-1075
21. Lin SL, Chiang A, Chang D, Ying SY (2008) Loss of miR-146a function in hormone-refractory prostate cancer. RNA 14:417-424 (Pubitemid 351397806)
22. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M (2001) Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Pract 52:119-123 (Pubitemid 32366481)
23. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751
24. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF Alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111-1116 (Pubitemid 26070591)
25. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK (2005) Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939-2945 (Pubitemid 41401090)
26. Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, Pedersen BK (2003) Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124:495-502 (Pubitemid 36514904)
27. Huang Y, Li T, Sane DC, Li L (2004) IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem 279:51697-51703 (Pubitemid 40017921)
28. Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM (2007) The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp Mol Pathol 82:280-283 (Pubitemid 46686662)
29. Liu S, Lutz J, Chang J, Liu D, Heemann U, Baumann M (2010) TRAF6 knockdown promotes survival and inhibits inflammatory response to lipopolysaccharides in rat primary renal proximal tubule cells. Acta Physiol (Oxf) 199:339-346
30. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet induced insulin resistance with salicylates or targeted disruption of IkkB. Science 293:1673-1677 (Pubitemid 32807849)
31. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKKB and NF-kB. Nat Med 11:183-190 (Pubitemid 40321354)
32. Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A, Nawroth PP (1998) Insufficient glycemic control increases nuclear factor k B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 21:1310-1316 (Pubitemid 28365689)
33. Adaikalakoteswari A, Rema M, Mohan V, Balasubramanyam M (2007) Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy. Int J Biochem Cell Biol 39:1673-1684 (Pubitemid 47088311)
34. Patel S, Santani D (2009) Role of NF-kappaB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 61:595-603
35. Lin R, Génin P, Mamane Y, Hiscott J (2000) Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol Cell Biol 20:6342-6353 (Pubitemid 30650221)
36. Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446 (Pubitemid 38738176)
37. Rønn SG, Börjesson A, Bruun C, Heding PE, Frobøse H, Mandrup-Poulsen T, Karlsen AE, Rasschaert J, Sandler S, Billestrup N (2008) Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 51:1873-1882
38. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez- Vizarra P, Mallavia B, Flores C, Sanz A, Blanco J, Mezzano S, Ortiz A, Egido J, Gomez-Guerrero C (2010) Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 21:763-772
39. Karlsen AE, Heding PE, Frobøse H, Rønn SG, Kruhøffer M, Orntoft TF, Darville M, Eizirik DL, Pociot F, Nerup J, Mandrup-Poulsen T, Billestrup N (2004) Suppressor of cytokine signalling (SOCS)-3 protects β cells against IL-1β-mediated toxicity through inhibition of multiple nuclear factor-kB-regulated proapoptotic pathways. Diabetologia 47:1998-2011 (Pubitemid 40110212)
40. Frobøse H, Rønn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, Billestrup N (2006) Suppressor of cytokine signaling- 3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 20:1587-1596 (Pubitemid 43967566)
41. Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA, Sommer SS, Rossi JJ (2009) SNPs in human miRNA genes affect biogenesis and function. RNA 15:1640-1651
42. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105:7269-7274 (Pubitemid 351754467)
43. Granjon A, Gustin MP, Rieusset J, Lefai E, Meugnier E, Güller I, Cerutti C, Paultre C, Disse E, Rabasa-Lhoret R, Laville M, Vidal H, Rome S (2009) The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway. Diabetes 58:2555-2564
44. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM (2009) Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 302:1186-1194